[Click eStock] "HK Innoen, P-CAB Targeting the US Market"

Yuanta Securities stated on the 10th that HK Innoen has proven the competitiveness of P-CAB in Japan and Korea, and expects growth in the U.S. market as well.

Researcher Ha Hyun-soo of Yuanta Securities explained, "P-CAB competitively binds to the potassium ion (K+) binding site of hydrogen-potassium ATPase, thereby inhibiting the secretion of hydrogen ions (H+) in the stomach," adding, "Unlike PPIs, it can act directly and binds reversibly to hydrogen-potassium ATPase, resulting in a rapid onset of efficacy."

He continued, "It maintains long-term effects compared to PPIs," and added, "Unlike PPIs, it is not affected by meals, which increases dosing convenience, and the domestic market share of P-CAB is continuously rising." Furthermore, he emphasized, "In Japan, where P-CAB was launched earlier than in Korea, the market share of P-CAB reached 33% in 2020," and "Annual sales of Takecab in Japan are approximately 700 million dollars."

Researcher Ha introduced, "The North American rights for K-CAB (Tegoprazan) have been transferred to Sebela (Braintree)," and "Currently, Phase 3 clinical trials are underway for non-erosive reflux disease (NERD) and erosive esophagitis (EE)." He analyzed, "Clinical results are expected to be confirmed in the second half of this year and the first half of next year, respectively," and "The proportion of severe EE patients will be increased in Phase 3 trials to verify the superior efficacy of P-CAB compared to PPIs." He also stated, "Strong marketing effects are expected after the launch."

This content was produced with the assistance of AI translation services.